Adverum Biotechnologies To Present LUNA 26-Week Phase 2 Interim Analysis At The ASRS Annual Scientific Meeting
Adverum Biotechnologies To Present LUNA 26-Week Phase 2 Interim Analysis At The ASRS Annual Scientific Meeting
Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present the 26-week landmark interim analysis from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD) at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting being held in Stockholm, Sweden from July 17 - 20, 2024.
Adverum Biotechnologenies, Inc.（纳斯达克股票代码：ADVM）是一家率先使用基因疗法作为高度流行的眼部疾病新护理标准的临床阶段公司，该公司今天宣布，该公司将在美国发表为期26周的具有里程碑意义的中期分析，该研究旨在治疗湿性年龄相关黄斑变性（湿性AMD）。视网膜专家协会（ASRS）年度科学会议将于2024年7月17日至20日在瑞典斯德哥尔摩举行。
ASRS Annual Scientific Meeting Presentation Information
ASRS 年度科学会议演示信息
Title: Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: First-Time 26-Week Interim Analysis Results From the Phase 2 LUNA Study
标题：新生血管 AMD 的 Ixoberogene Soroparvovec (ixo-VEC) IVT 基因疗法：LUNA 2 期研究的首次 26 周中期分析结果
Date / Time: Wednesday, July 17th, 2024 at 8:45am CEST
日期/时间：欧洲中部标准时间 2024 年 7 月 17 日星期三上午 8:45
Session: Wet AMD Symposium 1
会议：湿式 AMD 研讨会 1
Presenter: Charles C. Wykoff, MD, PhD, FASRS, Director of Research, Retina Consultants of Texas; Professor of Clinical Ophthalmology, Blanton Eye Institute, Houston Methodist Hospital
主持人：Charles C. Wykoff，医学博士，FASRS，德克萨斯州视网膜顾问研究总监；休斯敦卫理公会医院布兰顿眼科研究所临床眼科教授
The presentation will be available on the News and Publications section of Adverum's website shortly after the presentation.
演示结束后不久，该演示文稿将在Adverum网站的新闻和出版物栏目上发布。